Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Trevena Inc (TRVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,231
  • Shares Outstanding, K 92,354
  • Annual Sales, $ 5,730 K
  • Annual Income, $ -30,780 K
  • 60-Month Beta 2.61
  • Price/Sales 24.97
  • Price/Cash Flow N/A
  • Price/Book 3.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.27 +46.06%
on 02/28/19
1.94 -4.38%
on 03/19/19
+0.37 (+24.50%)
since 02/19/19
3-Month
0.38 +388.16%
on 12/24/18
1.94 -4.38%
on 03/19/19
+1.33 (+253.33%)
since 12/19/18
52-Week
0.38 +388.16%
on 12/24/18
3.58 -48.18%
on 10/03/18
+0.09 (+4.80%)
since 03/19/18

Most Recent Stories

More News
Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?

Is (TRVN) Outperforming Other Medical Stocks This Year?

TRVN : 1.79 (+7.19%)
PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y

PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.

TRVN : 1.79 (+7.19%)
CELG : 89.04 (+1.19%)
PDLI : 3.71 (+2.20%)
BIIB : 325.92 (+0.09%)
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why

Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.

TRVN : 1.79 (+7.19%)
CELG : 89.04 (+1.19%)
PBYI : 41.02 (-3.19%)
RHHBY : 33.7700 (-0.27%)
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

AGEN : 2.87 (-0.35%)
TRVN : 1.79 (+7.19%)
CELG : 89.04 (+1.19%)
GILD : 65.89 (+1.34%)
Trevena: 4Q Earnings Snapshot

CHESTERBROOK, Pa. (AP) _ Trevena Inc. (TRVN) on Wednesday reported a loss of $8 million in its fourth quarter.

TRVN : 1.79 (+7.19%)
Trevena Reports Fourth Quarter and Full Year 2018 Results

-- Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA --

TRVN : 1.79 (+7.19%)
Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine's Potential for Management of Moderate-to-Severe Acute Pain

Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system,...

TRVN : 1.79 (+7.19%)
Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019

Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced that it will release...

TRVN : 1.79 (+7.19%)
Will Trevena Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Trevena.

TRVN : 1.79 (+7.19%)
Biotech Stocks Set to Pop

HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the...

TRVN : 1.79 (+7.19%)
PTI : 4.27 (+2.40%)
NVLN : 1.20 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade TRVN with:

Business Summary

Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of...

See More

Key Turning Points

2nd Resistance Point 1.78
1st Resistance Point 1.72
Last Price 1.79
1st Support Level 1.58
2nd Support Level 1.50

See More

52-Week High 3.58
Fibonacci 61.8% 2.36
Fibonacci 50% 1.98
Last Price 1.79
Fibonacci 38.2% 1.60
52-Week Low 0.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar